Search Results - "BRAY, Mark R."

Targeting Mitosis in Cancer: Emerging Strategies by Dominguez-Brauer, Carmen, Thu, Kelsie L., Mason, Jacqueline M., Blaser, Heiko, Bray, Mark R., Mak, Tak W.

“…The cell cycle is an evolutionarily conserved process necessary for mammalian cell growth and development. Because cell-cycle aberrations are a hallmark of…”
Get full text

Functional Characterization of CFI-400945, a Polo-like Kinase 4 Inhibitor, as a Potential Anticancer Agent by Mason, Jacqueline M., Lin, Dan Chi-Chia, Wei, Xin, Che, Yi, Yao, Yi, Kiarash, Reza, Cescon, David W., Fletcher, Graham C., Awrey, Donald E., Bray, Mark R., Pan, Guohua, Mak, Tak W.

“…PLK4 was identified as a promising therapeutic target through a systematic approach that combined RNAi screening with gene expression analysis in human breast…”
Get full text

Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer by Mason, Jacqueline M., Wei, Xin, Fletcher, Graham C., Kiarash, Reza, Brokx, Richard, Hodgson, Richard, Beletskaya, Irina, Bray, Mark R., Mak, Tak W.

“…Loss of cell-cycle control is a hallmark of human cancer. Cell-cycle checkpoints are essential for maintaining genome integrity and balanced growth and…”
Get full text

Fcmr regulates mononuclear phagocyte control of anti-tumor immunity by Kubli, Shawn P., Vornholz, Larsen, Duncan, Gordon, Zhou, Wenjing, Ramachandran, Parameswaran, Fortin, Jerome, Cox, Maureen, Han, SeongJun, Nechanitzky, Robert, Nechanitzky, Duygu, Snow, Bryan E., Jones, Lisa, Li, Wanda Y., Haight, Jillian, Wakeham, Andrew, Bray, Mark R., Mak, Tak W.

“…Myeloid cells contribute to tumor progression, but how the constellation of receptors they express regulates their functions within the tumor…”
Get full text

The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3‑(4-(heterocyclyl)phenyl)‑1H‑indazole-5-carboxamides as Anticancer Agents by Liu, Yong, Lang, Yunhui, Patel, Narendra Kumar, Ng, Grace, Laufer, Radoslaw, Li, Sze-Wan, Edwards, Louise, Forrest, Bryan, Sampson, Peter B, Feher, Miklos, Ban, Fuqiang, Awrey, Donald E, Beletskaya, Irina, Mao, Guodong, Hodgson, Richard, Plotnikova, Olga, Qiu, Wei, Chirgadze, Nickolay Y, Mason, Jacqueline M, Wei, Xin, Lin, Dan Chi-Chia, Che, Yi, Kiarash, Reza, Madeira, Brian, Fletcher, Graham C, Mak, Tak W, Bray, Mark R, Pauls, Henry W

“…The acetamido and carboxamido substituted 3-(1H-indazol-3-yl)­benzenesulfonamides are potent TTK inhibitors. However, they display modest ability to attenuate…”
Get full text

2-Methoxyestradiol inhibits experimental autoimmune encephalomyelitis through suppression of immune cell activation by Duncan, Gordon S., Brenner, Dirk, Tusche, Michael W., Brüstle, Anne, Knobbe, Christiane B., Elia, Andrew J., Mock, Thomas, Bray, Mark R., Krammer, Peter H., Mak, Tak W.

“…The endogenous metabolite of estradiol, 2-Methoxyestradiol (2ME2), is an antimitotic and antiangiogenic cancer drug candidate that also exhibits…”
Get full text

Author Correction: Fcmr regulates mononuclear phagocyte control of anti-tumor immunity by Kubli, Shawn P., Vornholz, Larsen, Duncan, Gordon, Zhou, Wenjing, Ramachandran, Parameswaran, Fortin, Jerome, Cox, Maureen, Han, SeongJun, Nechanitzky, Robert, Nechanitzky, Duygu, Snow, Bryan E., Jones, Lisa, Li, Wanda Y., Haight, Jillian, Wakeham, Andrew, Bray, Mark R., Mak, Tak W.

“…An amendment to this paper has been published and can be accessed via a link at the top of the paper…”
Get full text

Predictive Biomarkers of Sensitivity to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Breast Cancer Models by DIAMOND, Jennifer R, GAIL ECKHARDT, S, FLETCHER, Graham C, TENTLER, John J, CHOON TAN, Aik, NEWTON, Timothy P, SELBY, Heather M, BRUNKOW, Kelsey L, KACHAEVA, Maria I, VARELLA-GARCIA, Marileila, PITTS, Todd M, BRAY, Mark R

“…The Aurora kinases are a family of conserved serine-threonine kinases with key roles in mitotic cell division. As with other promising anticancer targets,…”
Get full text

ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer by Matulonis, Ursula A, Lee, Julie, Lasonde, Brian, Tew, William P, Yehwalashet, Afra, Matei, Daniela, Behbakht, Kian, Grothusen, Jill, Fleming, Gini, Lee, Nita K, Arnott, Jamie, Bray, Mark R, Fletcher, Graham, Brokx, Richard D, Castonguay, Vincent, Mackay, Helen, Sidor, Carolyn F, Oza, Amit M

“…Abstract Purpose The purpose was to assess the activity and side effect profile of ENMD-2076, an oral anti-angiogenic and anti-proliferative kinase inhibitor,…”
Get full text

Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD‐2076, against multiple myeloma by Wang, Xiaojing, Sinn, Anthony L., Pollok, Karen, Sandusky, George, Zhang, Shuhong, Chen, Li, Liang, Jing, Crean, Colin D., Suvannasankha, Attaya, Abonour, Rafat, Sidor, Carolyn, Bray, Mark R., Farag, Sherif S.

“…Summary ENMD‐2076 is a novel, orally‐active molecule that has been shown to have significant activity against aurora and multiple receptor tyrosine kinases. We…”
Get full text

Assessment of the In vivo Antitumor Effects of ENMD-2076, a Novel Multitargeted Kinase Inhibitor, against Primary and Cell Line-Derived Human Colorectal Cancer Xenograft Models by TENTLER, John J, BRADSHAW-PIERCE, Erica L, SERKOVA, Natalie J, HASEBROOCK, Kendra M, PITTS, Todd M, DIAMOND, Jennifer R, FLETCHER, Graham C, BRAY, Mark R, ECKHARDT, S. Gail

“…This in vivo study was designed to investigate the efficacy of ENMD-2076, a small-molecule kinase inhibitor with activity against the Aurora kinases A and B,…”
Get full text

Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial by Veitch, Zachary W., Cescon, David W., Denny, Trisha, Yonemoto, Lisa-Maria, Fletcher, Graham, Brokx, Richard, Sampson, Peter, Li, Sze-Wan, Pugh, Trevor J., Bruce, Jeffrey, Bray, Mark R., Slamon, Dennis J., Mak, Tak W., Wainberg, Zev A., Bedard, Philippe L.

“…Background CFI-400945 is a first-in-class oral inhibitor of polo-like kinase 4 (PLK4) that regulates centriole duplication. Primary objectives of this…”
Get full text

Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair-Deficient Uterine Leiomyosarcoma by Lee, Horace H Y, Chow, Kin Long, Wong, Ho Shing, Chong, Tsz Yan, Wong, Alice S T, Cheng, Grace H W, Ko, Jasmine M K, Siu, Hoi Cheong, Yeung, Maximus C F, Huen, Michael S Y, Tse, Ka Yu, Bray, Mark R, Mak, Tak Wah, Leung, Suet Yi, Ip, Philip P C

“…Uterine leiomyosarcoma (LMS) is an aggressive sarcoma and a subset of which exhibits DNA repair defects. Polo-like kinase 4 (PLK4) precisely modulates mitosis,…”
Get full text

Polo-like kinase 4 inhibitor CFI-400945 suppresses liver cancer through cell cycle perturbation and eliciting antitumor immunity by Chan, Cerise Yuen-Ki, Yuen, Vincent Wai-Hin, Chiu, David Kung-Chun, Goh, Chi-Ching, Thu, Kelsie L, Cescon, David W, Soria-Bretones, Isabel, Law, Cheuk-Ting, Cheu, Jacinth Wing-Sum, Lee, Derek, Tse, Aki Pui-Wah, Tan, Kel Vin, Zhang, Misty Shuo, Wong, Bowie Po-Yee, Wong, Chun-Ming, Khong, Pek-Lan, Ng, Irene Oi-Lin, Bray, Mark R, Mak, Tak Wah, Yau, Thomas Chung-Cheung, Wong, Carmen Chak-Lui

“…Prognosis of HCC remains poor due to lack of effective therapies. Immune checkpoint inhibitors (ICIs) have delayed response and are only effective in a subset…”
Get full text

Analysis of binding of the family 2a carbohydrate-binding module from Cellulomonas fimi xylanase 10A to cellulose: specificity and identification of functionally important amino acid residues by McLean, Bradley W., Bray, Mark R., Boraston, Alisdair B., Gilkes, Neil R., Haynes, Charles A., Kilburn, Douglas G.

“…The family 2a carbohydrate-binding module (CBM2a) of xylanase 10A from Cellulomonas fimi binds to the crystalline regions of cellulose. It does not share…”
Get full text

Preclinical characterization and clinical trial of CFI-400945, a polo-like kinase 4 inhibitor, in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic neoplasms by Murphy, Tracy, Mason, Jacqueline M., Leber, Brian, Bray, Mark R., Chan, Steven M., Gupta, Vikas, Khalaf, Dina, Maze, Dawn, McNamara, Caroline J., Schimmer, Aaron D., Schuh, Andre C., Sibai, Hassan, Trus, Michael, Valiquette, Debbie, Martin, Kylie, Nguyen, Linh, Li, Xuan, Mak, Tak W., Minden, Mark D., Yee, Karen W. L.

“…CFI-400945 is a selective oral polo-like kinase 4 (PLK4) inhibitor that regulates centriole duplication. PLK4 is aberrantly expressed in patients with acute…”
Get full text

Identification of KIFC1 as a putative vulnerability in lung cancers with centrosome amplification by Zhang, Christopher, Wu, Benson Z., Di Ciano-Oliveira, Caterina, Wu, Yin Fang, Khavkine Binstock, Sharon S., Soria-Bretones, Isabel, Pham, Nhu-An, Elia, Andrew J., Chari, Raj, Lam, Wan L., Bray, Mark R., Mak, Tak W., Tsao, Ming-Sound, Cescon, David W., Thu, Kelsie L.

“…Centrosome amplification (CA), an abnormal increase in the number of centrosomes in the cell, is a recurrent phenomenon in lung and other malignancies…”
Get full text

ENMD-2076 is an orally active kinase inhibitor with antiangiogenic and antiproliferative mechanisms of action by Fletcher, Graham C, Brokx, Richard D, Denny, Trisha A, Hembrough, Todd A, Plum, Stacy M, Fogler, William E, Sidor, Carolyn F, Bray, Mark R

“…ENMD-2076 is a novel orally active, small molecule kinase inhibitor with a mechanism of action involving several pathways key to tumor growth and survival:…”
Get full text

DJ-1, a novel regulator of the tumor suppressor PTEN by Kim, Raymond H., Peters, Malte, Jang, YingJu, Shi, Wei, Pintilie, Melania, Fletcher, Graham C., DeLuca, Carmela, Liepa, Jennifer, Zhou, Lily, Snow, Bryan, Binari, Richard C., Manoukian, Armen S., Bray, Mark R., Liu, Fei-Fei, Tsao, Ming-Sound, Mak, Tak W.

“…The phosphatidylinositol 3′ kinase (PI3′K) pathway, which regulates cell survival, is antagonized by the PTEN tumor suppressor. The regulation of PTEN is…”
Get full text

Overexpression of AKT2/protein kinase Bβ leads to up-regulation of β1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells by ARBOLEDA, M. Jane, LYONS, John F, KABBINAVAR, Fairooz F, BRAY, Mark R, SNOW, Bryan E, AYALA, Raul, DANINO, Mordechai, KARLAN, Beth Y, SLAMON, Dennis J

Get full text